Pan S, Wang S, Li W, et al. - In patients suffering from stage II (N1+) non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutation, researchers wanted to clarify if icotinib is superior to cisplatin plus docetaxel as adjuvant chemotherapy. This cohort included 43 participants with completely resected stage II (T1-2N1M0) NSCLC and confirmed sensitive EGFR mutation (19Del or L858R). In 22 patients managed with icotinib and 21 who received cisplatin plus docetaxel, disease-free survival (DFS) and overall survival were assessed. A significantly longer survival time was evident in the icotinib group vs in the chemotherapy group, with a median DFS of 47 months vs 18 months. Findings indicate that an advantage in terms of DFS and decreased drug toxicity might be offered by icotinib vs cisplatin plus docetaxel in EGFR mutation-positive patients with completely resected stage II (T1-2N1M0) NSCLC, making icotinib a reasonable choice for adjuvant chemotherapy in these patients.